Regencell Bioscience Holdings

RGC · NASDAQ

$7.67−$2.14 (−21.81%)TodayMarket closed ·
Prev close $9.81

About RGC

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company employs 10 full-time employees The company went IPO on 2021-07-16. The firm launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.

Employees
10
Headquarters
Hong Kong
Listed
Jul 16, 2021
Sector
Health Care
Industry
Pharmaceuticals

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.